Patients with septicemia or severe infection
Patients with septicemia or severe infection
Severe infection within  weeks prior to randomization
Severe infection within  weeks prior to initiation of study treatment;
Severe infection within  weeks before initiation of study treatment
Severe infection within  weeks prior to randomization
Severe infection within  weeks prior to initiation of study treatment
Severe infection within  weeks prior to enrollment
Severe acute infection
Severe infections within  weeks prior to enrollment;
Uncontrolled active infection (i.e., progressive symptoms related to infection despite treatment or persistently positive microbiological cultures despite treatment or any other evidence of severe sepsis).
Severe infection within  weeks prior to initiation of study treatment
Severe infection within  weeks prior to enrollment
TREATMENT: Patients with severe active infection
Active uncontrolled infection or severe infection disease (e.g., severe pneumonia, meningitis, septicemia, or methicillin resistant Staphylococcus aureus infection)
Severe infection within  weeks prior to initiation of study treatment
Severe infection within  weeks prior to D of C
Severe infection within  weeks prior to randomization
Severe infections within  weeks prior to randomization
Severe acute infection
Severe active viral infection, especially hepatitis B; severe infection (such as sepsis, pneumonia, etc.) should be clinically controlled at the time of randomization; contact the national co-investigator for further advice if necessary
Severe systemic infection (i.e., sepsis)
Patients with sepsis or severe infection
Severe systemic infections, current or within the two weeks prior to initiation of AEB.
Patients with sepsis or severe infection
Patients with sepsis or severe infection
Severe infection within  weeks prior to randomization
Patients with sepsis or severe infection
